Market Overview

UPDATE: Citigroup Initiates Ariad Pharmaceuticals at Buy

Related ARIA
Mid-Day Market Update: Dave & Buster's Climbs On Upbeat Results; Sigma Designs Shares Slide
Bernie Sanders' 'Trump Proposal' To Lower Drug Prices Blocked By Senate Republicans
Ariad Pharma Could Draw M&A Fire Ahead Of Second Cancer Drug Win (Investor's Business Daily)

Citigroup initiated coverage on Ariad Pharmaceuticals (NASDAQ: ARIA) with a Buy rating and a $31 price target.

Citigroup noted, "We believe ARIA's ponatinib is "best in class" in the ~$5bn WW leukemia (CML) market and our outlook is higher than consensus. Initial FDA/EU ponatinib approvals are widely expected by 1Q:13 and 2H:13 respectively, but a potential broader drug label would be upside to consensus, in our view. We expect ponatinib's Ph3 1st-line CML trial will stop early (2014) adding an additional ~$400M in 1st-line sales by 2018. We believe ARIA's lung cancer drug AP26113 is superior to PFE's Xalkori (crizotinib). Its dual mechanism also targets other lung cancer populations >3X crizotinib's market. With crizotinib `15 consensus estimates reaching ~$700M, our 2017 risk-adjusted AP26113 sales estimate of $240M is not a stretch."

Ariad Pharmaceuticals closed at $21.97 on Thursday.

Latest Ratings for ARIA

Nov 2016Deutsche BankInitiates Coverage OnHold
Oct 2016JMP SecuritiesDowngradesMarket OutperformMarket Perform
Oct 2016JP MorganDowngradesNeutralUnderweight

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (ARIA)

View Comments and Join the Discussion!